Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05885464 · ClinicalTrials.gov registry record · Phase 1

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

A Phase 1 study of Lymphoblastic Lymphoma and Lymphoblastic Leukemia, sponsored by Beam Therapeutics.

Active
Registry status
Phase 1
Development phase
5
Enrollment target
10
Study locations

NCT05885464 is a Phase 1 study of Lymphoblastic Lymphoma and Lymphoblastic Leukemia that is active but no longer recruiting, run by Beam Therapeutics. The registered enrollment target is 5 participants, below the 192-participant average among 21 other Lymphoblastic Lymphoma trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05885464, a Phase 1 study of Lymphoblastic Lymphoma and Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by Beam Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
5 participants
Enrollment target
10
Study locations

Study Summary

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to \< 12 years), and a Phase 2 cohort.

Conditions Studied

Lymphoblastic Lymphoma Lymphoblastic Leukemia T-Cell Lymphoblastic Leukemia/Lymphoma

Interventions

  • BIOLOGICAL BEAM-201

Study Locations (10)

California

  • Stanford University School of Medicine - Stanford

Colorado

  • Colorado Blood Cancer Institute - Denver

Illinois

  • University of Chicago - Chicago

Kansas

  • The University of Kansas Cancer Center - Fairway

Massachusetts

  • Dana Farber and Boston Children's Hospital - Boston

Ohio

  • Cleveland Clinic- Taussig Cancer Center - Cleveland

Oregon

  • OHSU Knight Cancer Institute Hematology Oncology - Portland

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2023-05-25
Est. Completion 2026-12
Phase Phase 1

Sponsor

Beam Therapeutics

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05885464

The ClinicalTrials.gov registry entry for NCT05885464 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 21 other Lymphoblastic Lymphoma trials with a reported enrollment target (97% lower). The listed sponsor is Beam Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Lymphoblastic Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which BEAM-201 is the first listed.

NCT05885464 reports 10 study locations spanning 10 distinct geographic areas - top geographies include California, Colorado, Illinois.

Frequently Asked Questions

What is clinical trial NCT05885464 about?

NCT05885464 is a clinical study titled "A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)". This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to...

What is the current status of trial NCT05885464?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2023-05-25. Estimated completion is 2026-12.

What conditions does trial NCT05885464 study?

This clinical trial studies the following conditions: Lymphoblastic Lymphoma, Lymphoblastic Leukemia, T-Cell Lymphoblastic Leukemia/Lymphoma.

What interventions are being tested in trial NCT05885464?

The interventions under investigation include: BEAM-201 (BIOLOGICAL).

Who is sponsoring clinical trial NCT05885464?

This trial is sponsored by Beam Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05885464 being conducted?

This trial has 10 study locations across California, Colorado, Illinois, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoblastic Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoblastic Lymphoma

All registered trials for this condition

Lymphoblastic Leukemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.